QQQ   444.85 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
QQQ   444.85 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
QQQ   444.85 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
QQQ   444.85 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
NASDAQ:LMDX

LumiraDx (LMDX) Stock Price, News & Analysis

$0.0076
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$0.0076
$0.0086
50-Day Range
$0.0076
$0.0171
52-Week Range
$0.02
$1.33
Volume
832,066 shs
Average Volume
56.75 million shs
Market Capitalization
$2.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.75
LMDX stock logo

About LumiraDx Stock (NASDAQ:LMDX)

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.

LMDX Stock Price History

LMDX Stock News Headlines

LMDX.O
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Why Is LumiraDx (LMDX) Stock Down 13% Today?
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
LumiraDx Agrees To Sell Point-of-Care Tech Platform To Roche
LumiraDx Limited (LMDX)
LumiraDx Ltd LMDX
What Makes LumiraDx Limited (LMDX) a New Buy Stock
See More Headlines
Receive LMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/24/2023
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LMDX
Fax
N/A
Employees
1,210
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.75
High Stock Price Target
$2.70
Low Stock Price Target
$0.80
Potential Upside/Downside
+22,926.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-447,790,000.00
Net Margins
-268.45%
Pretax Margin
-264.58%

Debt

Sales & Book Value

Annual Sales
$126.52 million
Book Value
($0.33) per share

Miscellaneous

Free Float
205,749,000
Market Cap
$2.42 million
Optionable
Not Optionable
Beta
1.73
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Ms. Veronique Ameye EMBA (Age 46)
    Esq., M.B.A., CEO & General Counsel
  • Mr. Dorian LeBlanc CPA (Age 48)
    CFO & VP of Global Operations
  • Ms. Colleen McMillen
    Vice President of Communications
  • Andy Ward
    National Sales Director - UK
  • Mr. David Walton DMS (Age 69)
    Chief Commercial Officer
  • Giffin Daughtridge
    President of North America Commercial Operations & Global Molecular Solutions
  • Melissa Garcia
    VP & Corporate Counsel

LMDX Stock Analysis - Frequently Asked Questions

Should I buy or sell LumiraDx stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LumiraDx in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LMDX shares.
View LMDX analyst ratings
or view top-rated stocks.

What is LumiraDx's stock price target for 2024?

1 brokers have issued 12-month target prices for LumiraDx's shares. Their LMDX share price targets range from $0.80 to $2.70. On average, they expect the company's stock price to reach $1.75 in the next twelve months. This suggests a possible upside of 22,926.3% from the stock's current price.
View analysts price targets for LMDX
or view top-rated stocks among Wall Street analysts.

How have LMDX shares performed in 2024?

LumiraDx's stock was trading at $0.0629 on January 1st, 2024. Since then, LMDX shares have decreased by 87.9% and is now trading at $0.0076.
View the best growth stocks for 2024 here
.

How were LumiraDx's earnings last quarter?

LumiraDx Limited (NASDAQ:LMDX) issued its quarterly earnings data on Thursday, August, 24th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.01. The firm had revenue of $21 million for the quarter, compared to analyst estimates of $21.07 million. During the same quarter in the prior year, the business posted ($0.58) earnings per share.

Who are LumiraDx's major shareholders?

LumiraDx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Senvest Management LLC (2.53%).

How do I buy shares of LumiraDx?

Shares of LMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LMDX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners